EN
FR

Search terms

Vereos Digital PET/CT

Proven accuracy inspires confidence

Supported by rigorous clinical evidence, Vereos is the world’s first and only fully digital, clinically proven, PET/CT solution . With proprietary Digital Photon Counting technology for outstanding advances all along the imaging chain, Vereos exemplifies an established total solution to reveal more, earlier, to help you improve patient care and manage costs.

Contact us
Features
Improved lesion detectability

Improved lesion detectability

While visualization of small lesions is essential for clinicians to diagnose, stage and monitor therapy in oncology patients, in molecular imaging, the challenge is being able to detect these small lesions reliably [1]. Vereos provides improved detectability & characterization of small lesions [2]

Improved lesion detectability

While visualization of small lesions is essential for clinicians to diagnose, stage and monitor therapy in oncology patients, in molecular imaging, the challenge is being able to detect these small lesions reliably [1]. Vereos provides improved detectability & characterization of small lesions [2]

Improved lesion detectability

While visualization of small lesions is essential for clinicians to diagnose, stage and monitor therapy in oncology patients, in molecular imaging, the challenge is being able to detect these small lesions reliably [1]. Vereos provides improved detectability & characterization of small lesions [2]
Low PET dose

Low PET dose

Dose reduction in PET radiopharmaceutical administration does not have to be a trade-off between radiation exposure and diagnostic image quality. Utilizing appropriate reconstruction algorithms, reduced dose can be administered with no reduction in diagnostic confidence. Vereos provides uncompromised lesion detectability & quantification at 1/2 the PET dose [3]

Low PET dose

Dose reduction in PET radiopharmaceutical administration does not have to be a trade-off between radiation exposure and diagnostic image quality. Utilizing appropriate reconstruction algorithms, reduced dose can be administered with no reduction in diagnostic confidence. Vereos provides uncompromised lesion detectability & quantification at 1/2 the PET dose [3]

Low PET dose

Dose reduction in PET radiopharmaceutical administration does not have to be a trade-off between radiation exposure and diagnostic image quality. Utilizing appropriate reconstruction algorithms, reduced dose can be administered with no reduction in diagnostic confidence. Vereos provides uncompromised lesion detectability & quantification at 1/2 the PET dose [3]
Fast scans

Fast scans

Fast scanning allows patients to spend less time in the scanner, enhancing the overall patient experience. Vereos provides uncompromised lesion detectability at 1/10 the time [4]

Fast scans

Fast scanning allows patients to spend less time in the scanner, enhancing the overall patient experience. Vereos provides uncompromised lesion detectability at 1/10 the time [4]

Fast scans

Fast scanning allows patients to spend less time in the scanner, enhancing the overall patient experience. Vereos provides uncompromised lesion detectability at 1/10 the time [4]
Ready for the future

Ready for the future

With the highest count rate in the industry , Vereos provides enhanced diagnostic confidence with emerging applications that use short half-life tracers.

Ready for the future

With the highest count rate in the industry , Vereos provides enhanced diagnostic confidence with emerging applications that use short half-life tracers.

Ready for the future

With the highest count rate in the industry , Vereos provides enhanced diagnostic confidence with emerging applications that use short half-life tracers.
  • Improved lesion detectability
  • Low PET dose
  • Fast scans
  • Ready for the future
See all features
Improved lesion detectability

Improved lesion detectability

While visualization of small lesions is essential for clinicians to diagnose, stage and monitor therapy in oncology patients, in molecular imaging, the challenge is being able to detect these small lesions reliably [1]. Vereos provides improved detectability & characterization of small lesions [2]

Improved lesion detectability

While visualization of small lesions is essential for clinicians to diagnose, stage and monitor therapy in oncology patients, in molecular imaging, the challenge is being able to detect these small lesions reliably [1]. Vereos provides improved detectability & characterization of small lesions [2]

Improved lesion detectability

While visualization of small lesions is essential for clinicians to diagnose, stage and monitor therapy in oncology patients, in molecular imaging, the challenge is being able to detect these small lesions reliably [1]. Vereos provides improved detectability & characterization of small lesions [2]
Low PET dose

Low PET dose

Dose reduction in PET radiopharmaceutical administration does not have to be a trade-off between radiation exposure and diagnostic image quality. Utilizing appropriate reconstruction algorithms, reduced dose can be administered with no reduction in diagnostic confidence. Vereos provides uncompromised lesion detectability & quantification at 1/2 the PET dose [3]

Low PET dose

Dose reduction in PET radiopharmaceutical administration does not have to be a trade-off between radiation exposure and diagnostic image quality. Utilizing appropriate reconstruction algorithms, reduced dose can be administered with no reduction in diagnostic confidence. Vereos provides uncompromised lesion detectability & quantification at 1/2 the PET dose [3]

Low PET dose

Dose reduction in PET radiopharmaceutical administration does not have to be a trade-off between radiation exposure and diagnostic image quality. Utilizing appropriate reconstruction algorithms, reduced dose can be administered with no reduction in diagnostic confidence. Vereos provides uncompromised lesion detectability & quantification at 1/2 the PET dose [3]
Fast scans

Fast scans

Fast scanning allows patients to spend less time in the scanner, enhancing the overall patient experience. Vereos provides uncompromised lesion detectability at 1/10 the time [4]

Fast scans

Fast scanning allows patients to spend less time in the scanner, enhancing the overall patient experience. Vereos provides uncompromised lesion detectability at 1/10 the time [4]

Fast scans

Fast scanning allows patients to spend less time in the scanner, enhancing the overall patient experience. Vereos provides uncompromised lesion detectability at 1/10 the time [4]
Ready for the future

Ready for the future

With the highest count rate in the industry , Vereos provides enhanced diagnostic confidence with emerging applications that use short half-life tracers.

Ready for the future

With the highest count rate in the industry , Vereos provides enhanced diagnostic confidence with emerging applications that use short half-life tracers.

Ready for the future

With the highest count rate in the industry , Vereos provides enhanced diagnostic confidence with emerging applications that use short half-life tracers.

Specifications

Scanner Characteristics
Scanner Characteristics
Gantry with table dimensions
  • Length: 484.9 cm
  • Width: 220.3 cm
  • Height: 206.5 cm
Weight
  • 4,211 kg
Key specifications
Key specifications
Detector design
  • Digital Photon Counting (DPC)
Number of PET detectors
  • 23,040
PET timing resolution
  • 310 ps FWHM
TOF localization accuracy
  • 4.6 cm
PET effective sensitivity per cm
  • 1,427 cps/MBq/cm
PET quantitative accuracy
  • +/- 5%
Scanner Characteristics
Scanner Characteristics
Gantry with table dimensions
  • Length: 484.9 cm
  • Width: 220.3 cm
  • Height: 206.5 cm
Weight
  • 4,211 kg
Key specifications
Key specifications
Detector design
  • Digital Photon Counting (DPC)
Number of PET detectors
  • 23,040
See all specifications
Scanner Characteristics
Scanner Characteristics
Gantry with table dimensions
  • Length: 484.9 cm
  • Width: 220.3 cm
  • Height: 206.5 cm
Weight
  • 4,211 kg
Key specifications
Key specifications
Detector design
  • Digital Photon Counting (DPC)
Number of PET detectors
  • 23,040
PET timing resolution
  • 310 ps FWHM
TOF localization accuracy
  • 4.6 cm
PET effective sensitivity per cm
  • 1,427 cps/MBq/cm
PET quantitative accuracy
  • +/- 5%
  • [1] Hussain T, Nguyen QT. Molecular Imaging for Cancer Diagnosis and Surgery. Advanced drug delivery reviews. 2014;66:90-100. doi:10.1016/j.addr.2013.09.007.
  • [2] Nguyen NC,  Image Quality and Diagnostic Performance of a Digital PET Prototype in Patients with Oncologic Diseases: Initial Experience and Comparison with Analog PET, J Nucl Med 2015; 56:1378–1385
  • [3] Knopp,M, Binzel,K, Bardos,P, Knopp,M, Wright,C, Zhang,J, Nagar,V, Hall,N, Maniawski,P, Next Generation Digital PET/CT: A Phase I Intra-Individual Comparison with Current Photomultiplier TOF PET/CT. Radiological Society of North America 2015 Scientific Assembly and Annual Meeting, November 29 - December 4, 2015, Chicago IL.
  • [4] Zhang J., Evaluation of speed of PET acquisition: How fast can we go? - A validation of list mode PET simulation approach with true acquisitions, SNMMI 2017

By clicking on the link, you will be leaving the official Philips Electronics Ltd. ("Philips") website. Any links to third-party websites that may appear on this site are provided only for your convenience and in no way represent any affiliation or endorsement of the information provided on those linked websites. Philips makes no representations or warranties of any kind with regard to any third-party websites or the information contained therein.

I understand

You are about to visit a Philips global content page

Continue

You are about to visit the Philips USA website.

I understand

By clicking on the link, you will be leaving the official Philips Electronics Ltd. ("Philips") website. Any links to third-party websites that may appear on this site are provided only for your convenience and in no way represent any affiliation or endorsement of the information provided on those linked websites. Philips makes no representations or warranties of any kind with regard to any third-party websites or the information contained therein.

I understand

You are about to visit a Philips global content page

Continue

You are about to visit the Philips USA website.

I understand
© Koninklijke Philips N.V., 2004 - 2023. All rights reserved.

Our site can best be viewed with the latest version of Microsoft Edge, Google Chrome or Firefox.